Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort

[1]  R. Holle,et al.  Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies – A Novel Stepwise Approach by Evaluation of Medication , 2016, PloS one.

[2]  T. Welte,et al.  Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction. , 2016, JACC. Heart failure.

[3]  R. Holle,et al.  The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. , 2016, Respiratory medicine.

[4]  John A. Galdo,et al.  Hypoglycemic agents and potential anti-inflammatory activity , 2016, Journal of inflammation research.

[5]  P. Jones,et al.  Metformin in severe exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial , 2016, Thorax.

[6]  S. Couraud,et al.  Fonction pulmonaire du patient diabétique , 2016 .

[7]  S. Rees,et al.  Diffusion capacity of the lung for carbon monoxide – A potential marker of impaired gas exchange or of systemic deconditioning in chronic obstructive lung disease? , 2015, Chronic respiratory disease.

[8]  T. Asano,et al.  DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation. , 2015, American journal of physiology. Endocrinology and metabolism.

[9]  A. Díaz,et al.  Emphysema and DLCO predict a clinically important difference for 6MWD decline in COPD. , 2015, Respiratory medicine.

[10]  Alice M Turner,et al.  Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. , 2015, The Lancet. Respiratory medicine.

[11]  Y. Hattori,et al.  Pleiotropic Benefits of Metformin: Macrophage Targeting Its Anti-inflammatory Mechanisms , 2015, Diabetes.

[12]  J. Price,et al.  Association Between Severe Hypoglycemia, Adverse Macrovascular Events, and Inflammation in the Edinburgh Type 2 Diabetes Study , 2014, Diabetes Care.

[13]  P. Dey,et al.  Assessment of lung function by spirometry and diffusion study and effect of glycemic control on pulmonary function in type 2 diabetes mellitus patients of the eastern India. , 2014, Journal of clinical and diagnostic research : JCDR.

[14]  S. Qu,et al.  Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation. , 2014, World journal of gastroenterology.

[15]  Joyce D. Schroeder,et al.  Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus , 2014, BMC Pulmonary Medicine.

[16]  P. Metcalf,et al.  Respiratory Effects of Insulin Sensitisation with Metformin: A Prospective Observational Study , 2014, COPD.

[17]  E. Regan,et al.  Pulmonary Function Reduction in Diabetes With and Without Chronic Obstructive Pulmonary Disease , 2014, Diabetes Care.

[18]  C. Ramachandran,et al.  Alveolar Gas Exchange and Pulmonary Functions in Patients with Type II Diabetes Mellitus , 2013 .

[19]  Yuan-yuan Wang,et al.  Up-regulated ATP-sensitive potassium channels play a role in increased inflammation and plaque vulnerability in macrophages. , 2013, Atherosclerosis.

[20]  H. Völzke,et al.  Static lung volumes and airway resistance reference values in healthy adults , 2013, Respirology.

[21]  A. S,et al.  Alveolar Gas Exchange and Pulmonary Functions in Patients with Type II Diabetes Mellitus. , 2013, Journal of clinical and diagnostic research : JCDR.

[22]  S. Stanojevic,et al.  Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[23]  Katarzyna J. Macura,et al.  Role of computed tomography in quantitative assessment of emphysema , 2012, Polish journal of radiology.

[24]  N. Voelkel,et al.  COPD/emphysema: The vascular story , 2011, Pulmonary circulation.

[25]  M. Zeegers,et al.  Pulmonary function in diabetes: a metaanalysis. , 2010, Chest.

[26]  A. Ertl,et al.  Effects of Acute Hypoglycemia on Inflammatory and Pro-atherothrombotic Biomarkers in Individuals With Type 1 Diabetes and Healthy Individuals , 2010, Diabetes Care.

[27]  C. Vogelmeier,et al.  Einfluss systemischer Manifestationenund Komorbiditäten auf den klinischen Zustand und den Verlaufbei COPD , 2010 .

[28]  C. Vogelmeier,et al.  [Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease--an overview of the cohort study COSYCONET]. , 2010, Deutsche medizinische Wochenschrift.

[29]  J. Lammers,et al.  Diffusing capacity for nitric oxide: reference values and dependence on alveolar volume. , 2007, Respiratory medicine.

[30]  M. Katakura,et al.  Development, Worsening, and Improvement of Diabetic Microangiopathy in Older People: Six‐Year Prospective Study of Patients Under Intensive Diabetes Control , 2007, Journal of the American Geriatrics Society.

[31]  R. Landgraf,et al.  Pulmonary Function in Patients With Type 1 Diabetes Before and After Simultaneous Pancreas and Kidney Transplantation , 2007, Transplantation.

[32]  James L. Young,et al.  Metformin Inhibits Proinflammatory Responses and Nuclear Factor-&kgr;B in Human Vascular Wall Cells , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[33]  R. Pandey,et al.  Pulmonary functions in patients with type 2 diabetes mellitus & correlation with anthropometry & microvascular complications. , 2004, The Indian journal of medical research.

[34]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[35]  J. Christman,et al.  The Role of Nuclear Factor Kappa B in the Pathogenesis of Pulmonary Diseases: Implications for Therapy , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[36]  A. Aljada,et al.  Insulin Inhibits Intranuclear Nuclear Factor κB and Stimulates IκB in Mononuclear Cells in Obese Subjects: Evidence for an Anti-inflammatory Effect? , 2001 .

[37]  A. Aljada,et al.  Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? , 2001, The Journal of clinical endocrinology and metabolism.

[38]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[39]  K. Alberti,et al.  Lung function in patients with diabetes mellitus. , 1990, Respiratory medicine.

[40]  H. Janka.  [Macroangiopathy in diabetes mellitus]. , 1983, Die Medizinische Welt.